Business Wire

CA-ANDERSEN-GLOBAL

Del
Andersen Global forstærker sin afrikanske platform og tilføjer værdiansættelseskapacitet i Nigeria og Sydafrika

Andersen Global har tilføjet værdiansættelseskapacitet i Afrika og styrket sin overordnede regionale dækning ved at tilknytte ​​to nye samarbejdsvirksomheder – Nelson Thorpe Alonge i Nigeria og Valeo Capital i Sydafrika. Med disse tilføjelser markerer Andersen sine første udbud af værdiansættelsesservice i Afrika og og øger dermed virksomhedens udbud af global værdiansættelse i Nordamerika, Europa, Latinamerika, Mellemøsten og Asien.

Nelson Thorpe Alonge udbyder en komplet portefølje af værdiansættelse af aktiver, der dækker jord og bygninger, anlæg og udstyr, maritime aktiver, olie og gas, luftfart, ejendomsinvesteringer, ejendomsmæglervirksomhed, salg og opkøb, ejendoms- og facilitetsadministration samt rådgivning om ejendomsudstykning. Under ledelse af seniorpartner Victor Alonge betjener virksomheden selskaber, internationale agenturer, diplomatiske enheder, stater, statslige agenturer og personer med stor nettoformue.

"Kundernes succes og tilfredshed står i centrum af vores forretningsstrategi," siger Victor. "Vores samarbejde med Andersen Global er en milepæl for vores virksomhed og viser, at vi altid engagerer os maksimalt i forhold til vores kunder, når vi udvider vores virkeområde til at levere perfekte og omfattende værdiansættelsesløsninger globalt."

Valeo Capital er stiftet af de to partnere Riaan van Heerden og David Tosi og er en specialiseret virksomhed, der arbejder tæt sammen med kunder lige fra greenfieldvirksomheder til børsnoterede selskaber. Virksomheden yder omfattende virksomhedsfinansiering og -rådgivning, herunder fusioner og opkøb, BEE-ejerskabsstrukturering (black economic empowerment), værdiansættelse af virksomheder, due diligence og kapitalrejsning.

"Vi er stolte af den ressourcestyrke, pålidelighed og professionelle indsigt, vi giver til kunder og ønsker at fortsætte med at udvide vores udbud til kunder lokalt og globalt," siger Riaan. "Vores samarbejde med Andersen Global er en yderligere styrkelse af vores teams engagement i at yde klassens bedste service og fastholder vores konkurrencefordel i regionen."

Global Chairman og CEO for Andersen Mark L. Vorsatz siger: "Nelson Thorpe Alonge og Valeo Capital har konsekvent demonstreret deres forpligtelse på god forvaltning og kundeservice, og har skilt sig ud som førende på markedet. Både Nigeria og Sydafrika er som altid vigtige markeder, og virksomhedernes ekspertise er vigtig for vores globale ekspansionsstrategi og for at opfylde de skiftende værdiansættelseskrav fra kunder både regionalt og i udlandet."

Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skattejurister samt skatte- og værdiansættelseseksperter i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 17.000 eksperter i hele verden og en tilstedeværelse på over 475 lokaliteter gennem sine medlemsvirksomheder og samarbejdsvirksomheder.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240711008688/da/

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye